## Most Common Early Adverse Effect of Levodopa ### Nausea and Vomiting — The Most Frequent Early Toxicity **Key Point:** Nausea and vomiting occur in up to 80% of patients when levodopa is initiated without peripheral decarboxylase inhibitor (PDI) co-administration, and in 10–30% even with PDI. ### Mechanism of Nausea Levodopa is converted to dopamine in the **chemoreceptor trigger zone (CTZ)**, which lies outside the blood-brain barrier. Dopamine stimulation at the CTZ activates the vomiting centre. ### Prevention Strategy 1. **Always co-prescribe a peripheral decarboxylase inhibitor:** - Carbidopa (standard in India and most countries) - Benserazide (less common) 2. These PDIs do not cross the BBB, so they block peripheral conversion of levodopa to dopamine while allowing central conversion. 3. Ratio: Levodopa:Carbidopa typically 4:1 or 10:1. **Clinical Pearl:** The nausea typically subsides within 2–4 weeks as tolerance develops, even if the PDI is not used — but prophylaxis with PDI is standard practice. ### Timeline of Other Adverse Effects | Adverse Effect | Onset Timing | Incidence | |---|---|---| | Nausea/vomiting | Days to weeks | 10–30% (with PDI) | | Dyskinesias | Months to years | 40–80% after 5 years | | On-off fluctuations | Months to years | 50% after 5 years | | Psychosis | Variable, later | 5–15% overall | **High-Yield:** Dyskinesias and on-off fluctuations are **long-term complications** that emerge after months to years of therapy, not early adverse effects. ### Why Not the Other Options? - **Dyskinesias:** Develop after prolonged levodopa therapy (months to years), not in the first few weeks. - **On-off fluctuations:** A late complication related to pulsatile dopamine receptor stimulation; requires months of therapy to manifest. - **Psychosis:** Occurs in a minority of patients and is typically a late adverse effect, not the most common early one.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.